Intravenous keratinocyte growth factor protects against experimental pulmonary injury

Jane Guo, S. Yi Eunhee, Andrew M. Havill, Ildiko Sarosi, Lane Whitcomb, Songmei Yin, Scot C. Middleton, Pierre Piguet, Thomas R. Ulich

Research output: Contribution to journalArticlepeer-review

70 Scopus citations

Abstract

Keratinocyte growth factor (KGF) administered by intratracheal instillation is well documented to stimulate the proliferation of alveolar and bronchial cells. In the present study, intravenous KGF was also shown to stimulate the proliferation of alveolar and bronchial cells in mice and rats, although to a lesser degree than intratracheal KGF. Despite the decreased potency of intravenous KGF on pulmonary cell 5-bromo-2'-deoxyuridine incorporation compared with intratracheal KGF, intravenous KGF was very effective in preventing experimental bleomycin-induced pulmonary dysfunction, weight loss, and mortality in either mice or rats and experimental hyperoxia- induced mortality in mice. The effectiveness of intravenous administration of KGF in preventing lung injury suggests that the mechanisms of the protective effect of KGF may involve more than pulmonary cell proliferation and also suggests the potential use of systemic KGF for clinical trials in settings of pulmonary injury.

Original languageEnglish (US)
Pages (from-to)L800-L805
JournalAmerican Journal of Physiology - Lung Cellular and Molecular Physiology
Volume275
Issue number4 19-4
DOIs
StatePublished - 1998

Keywords

  • Bleomycin
  • Hyperoxia

ASJC Scopus subject areas

  • Physiology
  • Pulmonary and Respiratory Medicine
  • Physiology (medical)
  • Cell Biology

Fingerprint

Dive into the research topics of 'Intravenous keratinocyte growth factor protects against experimental pulmonary injury'. Together they form a unique fingerprint.

Cite this